Clinical trials: Hyperkeratosis
Ichthyosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
- Trial name
- NCT04697056
- Testing
- Imsidolimab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanda Pharmaceuticals
Actinic Keratosis
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive…
- Trial name
- NCT02120456
- Testing
- LEO 43204
- Where
- 21 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- LEO Pharma
Actinic Keratoses
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b)…
- Trial name
- NCT00948428
- Testing
- imiquimod, Aldara™, Vehicle Cream
- Where
- 20 sites in United States
- Volunteers
- 462 people
- Sponsor
- Actavis Inc.
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the…
- Trial name
- NCT03285490
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Bioequivalence Study of Two Imiquimod Cream 5%
The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00828568
- Testing
- Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
- Where
- 20 sites in United States
- Volunteers
- 425 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Actinic Keratosis
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00916006
- Testing
- PEP005 Gel, Vehicle gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 269 people
- Sponsor
- Peplin
Actinic Keratosis
A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase IIb study is designed to assess the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when applied to an area of skin, containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00700063
- Testing
- PEP005 Topical Gel, Vehicle gel
- Where
- 28 sites in United States, Australia
- Volunteers
- 265 people
- Sponsor
- Peplin
Netherton Syndrome
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older.
- Trial name
- NCT05856526
- Testing
- Spesolimab - solution for infusion, Spesolimab - solution for injection
- Where
- 28 sites in United States, Australia and 12 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Netherton Syndrome
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
Netherton syndrome is a genetic condition that can result in abnormal skin functioning. People with this condition often have red and scaling skin; sparse or short hair; and problems with absorption of medicines or chemicals that…
- Trial name
- NCT00208026
- Testing
- Pimecrolimus 1% Cream
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Children's Hospital of Philadelphia
Congenital Ichthyosis
A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin.
- Trial name
- NCT02864082
- Testing
- PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Patagonia Pharmaceuticals, LLC
Actinic Keratosis
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up.
- Trial name
- NCT02404389
- Testing
- Investigational Treatment, Active comparator
- Where
- 10 sites in Austria, Denmark and 3 more
- Volunteers
- 82 people
- Sponsor
- Novartis Pharmaceuticals
Netherton Syndrome
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
Netherton Syndrome (NS) is a severe rare disease characterized by generalized scaling, erythema, and epidermal barrier defects. This study assessed the safety, pharmacokinetics (PK), and efficacy of DS-2325a in patients with NS.
- Trial name
- NCT05979831
- Testing
- DS-2325a
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Daiichi Sankyo
Actinic Keratosis
Study of SOR007 Ointment for Actinic Keratosis
A Phase 2, randomized, double-blind, dose rising study to determine the safety, tolerability, and preliminary efficacy of four concentrations of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (SOR007) compared to SOR007…
- Trial name
- NCT03083470
- Testing
- SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- DFB Soria, LLC
Onychomycosis of Toenails
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01270971
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 27 sites in United States
- Volunteers
- 594 people
- Sponsor
- Pfizer
Actinic Keratosis
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
- Trial name
- NCT01600014
- Testing
- Ingenol mebutate gel, 0.015%, Vehicle gel
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 463 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Cryosurgery and Cream Combination for Actinic Keratosis
Carac 0.5% cream is approved for daily topical treatment of AK's for up to four weeks as tolerated, though local irritation often occurs within the first week of treatment and increases in a dose-dependent manner.
- Trial name
- NCT03037541
- Testing
- Carac Cream
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wake Forest University Health Sciences
Actinic Keratosis
Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)
The purpose of this study is to evaluate the safety and efficacy of BF-200 ALA (Ameluz) versus placebo in the field-directed treatment of mild to moderate actinic keratosis with photodynamic therapy (PDT) when using the…
- Trial name
- NCT01966120
- Testing
- BF-200 ALA gel, Photodynamic therapy with BF-RhodoLED
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Biofrontera Bioscience GmbH
Congenital Ichthyosis
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
The purpose of this study is to investigate the efficacy and safety of two concentrations of topically applied ointment formulation of isotretinoin called TMB-001 (0.05% and 0.1% isotretinoin) in subjects 9 years of age and older…
- Trial name
- NCT04154293
- Testing
- Isotretinoin, Vehicle
- Where
- 11 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
The aim of this study is to determine possible molecular changes on large scale gene expression profiling after treatment with Metvix photodynamic therapy (PDT) of actinic keratoses (AK) and cancerised field in renal transplant…
- Trial name
- NCT01000636
- Testing
- Metvix PDT
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Galderma R&D